Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Aquestive Therapeutics sees FY20 revenue $35M-$45M, consensus $38.42M » 16:23
08/04/20
08/04
16:23
08/04/20
16:23
AQST

Aquestive Therapeutics

$5.48 /

-0.19 (-3.35%)

Aquestive is re-affirming…

Aquestive is re-affirming its full year 2020 financial outlook. The Company's full year guidance does not include the revenue recognized this quarter as a result of minimum royalty payments that will be received over future years from KYNMOBI

ShowHide Related Items >><<
AQST Aquestive Therapeutics
$5.48 /

-0.19 (-3.35%)

AQST Aquestive Therapeutics
$5.48 /

-0.19 (-3.35%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
AQST Aquestive Therapeutics
$5.48 /

-0.19 (-3.35%)

  • 13
    Dec
AQST Aquestive Therapeutics
$5.48 /

-0.19 (-3.35%)

Earnings
Aquestive Therapeutics reports Q2 EPS (7c), consensus (43c) » 16:21
08/04/20
08/04
16:21
08/04/20
16:21
AQST

Aquestive Therapeutics

$5.48 /

-0.19 (-3.35%)

Reports Q2 revenue…

Reports Q2 revenue $21.7M, consensus $8.77M. Keith J. Kendall, President and Chief Executive Officer of Aquestive, stated, "While continuing to navigate the health crisis caused by the COVID-19 pandemic and, to the best of our ability, fulfilling our responsibility to keep our colleagues and neighbors safe, we are advancing the important work of the Company, as expected, and ensuring the medications our patients depend on each day remain available to them without interruption. We are pleased that Sympazan continued its commercial growth during the second quarter. Also, in July 2020, the FDA accepted our IND for AQST-108, our drug candidate in development to deliver systemic epinephrine for the treatment of anaphylaxis, and we are progressing toward commencing our planned PK trials expected later in the third quarter of this year. Concurrently, we are continuing to advance through the FDA review process for our product candidate, Libervant(TM) (diazepam) Buccal Film for the management of seizure clusters, including providing information to the agency, responding to its information requests and working with the agency on its inspection of our manufacturing and clinical investigational sites. With the commercial foundation we have built for Sympazan, we will be prepared to launch Libervant quickly, if approved by the FDA for U.S. marketing access. The formal process for a potential monetization of our KYNMOBI royalty asset is ongoing."

ShowHide Related Items >><<
AQST Aquestive Therapeutics
$5.48 /

-0.19 (-3.35%)

AQST Aquestive Therapeutics
$5.48 /

-0.19 (-3.35%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
AQST Aquestive Therapeutics
$5.48 /

-0.19 (-3.35%)

  • 13
    Dec
AQST Aquestive Therapeutics
$5.48 /

-0.19 (-3.35%)

Over a month ago
Hot Stocks
Aquestive CEO sees near-term value driven by CNS/epilepsy franchise » 08:43
07/02/20
07/02
08:43
07/02/20
08:43
AQST

Aquestive Therapeutics

$4.75 /

-0.11 (-2.26%)

Aquestive Therapeutics…

Aquestive Therapeutics (AQST) is a pharmaceutical company committed to developing and commercializing products to address unmet medical needs. In an exclusive interview with The Fly, Aquestive President and CEO Keith Kendall discussed the company and potential key value drivers: "The company has certainly been negatively impacted by a number of tangential events that are not in our control and, in some cases, not central to the key value drivers of the company. Aquestive is a fully integrated pharmaceutical company with multiple approved products, and additional pipeline candidates in development. Near-term value will be driven by the CNS/epilepsy franchise comprised of Sympazan, already launched, and Libervant, with its NDA currently pending at the FDA. Additionally, significant value has the potential to be created if we are successful in the development and launch of AQST-108 sublingual epinephrine, a potentially significant disruptive change to the historically injectable therapies currently available. Moreover, we believe that the company has significant opportunity to continue to provide innovative therapies in complex conditions beyond the programs currently in our pipeline, and we will consider augmenting our PharmFilm technology and know-how with other technologies in order to expand what we do for patients in our targeted therapeutic areas and other disease states. We expect that we will add other products to our pipeline over time, with a focus on under-treated conditions where our innovative drug delivery technology and know-how can create significant value for the patient." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company.

ShowHide Related Items >><<
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

  • 13
    Dec
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

Hot Stocks
Kendall sees potential value inflection points coming for Aquestive shareholders » 08:23
07/02/20
07/02
08:23
07/02/20
08:23
AQST

Aquestive Therapeutics

$4.75 /

-0.11 (-2.26%)

Aquestive Therapeutics…

Aquestive Therapeutics (AQST) is a pharmaceutical company committed to developing and commercializing products to address unmet medical needs. In an exclusive interview with The Fly, Aquestive President and CEO Keith Kendall discussed the company's business and cash position: "There are several things that are important to understand about our business. First, Aquestive has a proven track record of success in developing and manufacturing differentiated therapeutics with PharmFilm technology. We have five FDA approved therapeutics, both licensed and proprietary products. Second, we launched our first self-commercialized proprietary product, Sympazan, for the treatment of Lennox-Gastaut Syndrome in December 2018. Sympazan continues to grow and penetrate the market in which many prescribers will also be prescribers of Libervant when it is approved. Third, we continue to advance our late-stage pipeline of therapeutics for complex conditions. Libervant is the most advanced candidate in our pipeline, and, while there can be no assurances as to the decision the FDA may make, we hope to see it approved in September. Lastly, AQST-108, which could be the "first of its kind" oral version of epinephrine, will continue on its 505(b)(2) clinical and regulatory pathway following our recent IND filing with the FDA. We expect PK trials to begin later this year. Through a combination of our revenue, cash on hand and monetizable assets, we believe that we have capital or visibility to capital that will enable us to fund our business well into 2021 and possibly beyond. These, combined with some licensee activities, present a significant number of potential value inflection points for shareholders over the coming 12-24 months." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

ShowHide Related Items >><<
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

  • 13
    Dec
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

Hot Stocks
Aquestive CEO sees 'no reason' to believe Libervant PDUFA will be delayed » 08:00
07/02/20
07/02
08:00
07/02/20
08:00
AQST

Aquestive Therapeutics

$4.75 /

-0.11 (-2.26%)

Aquestive Therapeutics…

Aquestive Therapeutics (AQST) is a pharmaceutical company committed to developing and commercializing products to address unmet medical needs. In an exclusive interview with The Fly, Aquestive President and CEO Keith Kendall discussed the company's Libervant: "As we have indicated previously, the NDA for Libervant was filed in November 2019 and the FDA has assigned a PDUFA goal date of late September 2020. As an organization, we worked closely with the FDA during the development process to do our best to provide the information that the FDA needs to approve our product. However, there can be no assurances with regard to the FDA decision regarding our application. The review to-date has progressed as we would have expected, with a normal exchange of information requests and answers to the requests. We expect that this will continue as we move closer to the September date. At this time, we have no indication or reason to believe that there will be any delay." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

ShowHide Related Items >><<
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

  • 13
    Dec
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

Hot Stocks
Aquestive CEO says AQST-108 on track, PK trials to commence this year » 07:45
07/02/20
07/02
07:45
07/02/20
07:45
AQST

Aquestive Therapeutics

$4.75 /

-0.11 (-2.26%)

Aquestive Therapeutics…

Aquestive Therapeutics (AQST) is a pharmaceutical company committed to developing and commercializing products to address unmet medical needs. In an exclusive interview with The Fly, Aquestive President and CEO Keith Kendall discussed the company's AQST-108: "As we committed, the company announced on June 29 that we have submitted our IND application to the FDA for AQST-108. We continue to expect to commence PK clinical trials later in 2020. The COVID-19 pandemic has not affected our anticipated timelines on this product. AQST-108 represents a 'first of its kind' oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of anaphylaxis using Aquestive's proprietary PharmFilm technologies. We are excited about AQST-108's prospects based on the early proof of concept clinical trials we ran during 2018 and 2019, and the pre-IND meeting we held with the FDA in February 2020. In that meeting, we presented all of our development information to-date, and the FDA indicated no additional clinical work was necessary prior to filing our IND. The FDA also confirmed the application will be reviewed under the 505(b)(2) regulatory pathway. Additionally, the FDA acknowledged that there appears to be an unmet medical need among patients who resist the standard of care use of subcutaneous and intramuscular injection in the treatment of anaphylaxis. We believe that AQST-108 may potentially address some of those unmet needs. We plan to announce more about the program after the IND application has been accepted by the FDA, which is expected approximately 30 to 60 days after the filing date." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

ShowHide Related Items >><<
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

  • 13
    Dec
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

Hot Stocks
Aquestive CEO sees $50M-$100M from Parkinson's license royalties monetization » 07:25
07/02/20
07/02
07:25
07/02/20
07:25
AQST

Aquestive Therapeutics

$4.75 /

-0.11 (-2.26%)

Aquestive Therapeutics…

Aquestive Therapeutics (AQST) is a pharmaceutical company committed to developing and commercializing products to address unmet medical needs. In an exclusive interview with The Fly, Aquestive President and CEO Keith Kendall talked about the company's plans to advance its strategy to monetize the anticipated royalties associated with Sunovion Pharmaceuticals' apomorphine sublingual film APL-130277, which received FDA approval to treat motor fluctuations experienced by people living with Parkinson's disease. According to the executive: "As expected, Sunovion's Kynmobi product was approved by the FDA on May 21. Sunovion has announced its intention to launch the product in the U.S. in September of 2020. Sunovion licensed Aquestive Therapeutics' technology in order to develop Kynmobi. Based on the terms of our license agreement with Sunovion, we expect to receive a regular stream of royalties and license fees over the coming years from Kynmobi. These payments represent a potentially significant source of non-dilutive capital to Aquestive. We have begun the process to monetize the asset, and believe that the market is stabilizing so that we can expect to be in a position in the coming weeks to evaluate the timing and structure of a transaction that is the most advantageous to the company. Our expectation is that we will raise $50 to $100 million of gross proceeds from this monetization, subject to covenants in our debt agreements." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

ShowHide Related Items >><<
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

  • 13
    Dec
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

On The Fly
Meet Aquestive Therapeutics: A Fly exclusive interview with CEO Keith Kendall » 07:00
07/02/20
07/02
07:00
07/02/20
07:00
AQST

Aquestive Therapeutics

$4.75 /

-0.11 (-2.26%)

In an exclusive interview…

Open Full Text

ShowHide Related Items >><<
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

  • 13
    Dec
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

Hot Stocks
Near-term value should be driven by CNS/epilepsy franchise, Aquestive CEO says  07:00
07/02/20
07/02
07:00
07/02/20
07:00
AQST

Aquestive Therapeutics

$4.75 /

-0.11 (-2.26%)

 
ShowHide Related Items >><<
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

  • 13
    Dec
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

Hot Stocks
Aquestive CEO sees capital to fund business 'well into 2021'  07:00
07/02/20
07/02
07:00
07/02/20
07:00
AQST

Aquestive Therapeutics

$4.75 /

-0.11 (-2.26%)

 
ShowHide Related Items >><<
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

  • 13
    Dec
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.